Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults
IntroductionVaccine responses are often reduced in the elderly, leaving part of the elderly population vulnerable to infectious diseases. Timely vaccination may offer a solution for strengthening memory immunity before reaching old age, which classifies middle-aged persons as a target age group for...
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Frontiers Media S.A.
2017-07-01
|
| coleção: | Frontiers in Immunology |
| Assuntos: | |
| Acesso em linha: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00817/full |
| _version_ | 1831756617382625280 |
|---|---|
| author | Marieke van der Heiden Marieke van der Heiden Annemieke M. H. Boots Axel A. Bonacic Marinovic Lia G. H. de Rond Marjan van Maurik Irina Tcherniaeva Guy A. M. Berbers Anne-Marie Buisman |
| author_facet | Marieke van der Heiden Marieke van der Heiden Annemieke M. H. Boots Axel A. Bonacic Marinovic Lia G. H. de Rond Marjan van Maurik Irina Tcherniaeva Guy A. M. Berbers Anne-Marie Buisman |
| author_sort | Marieke van der Heiden |
| collection | DOAJ |
| description | IntroductionVaccine responses are often reduced in the elderly, leaving part of the elderly population vulnerable to infectious diseases. Timely vaccination may offer a solution for strengthening memory immunity before reaching old age, which classifies middle-aged persons as a target age group for vaccine interventions. However, knowledge regarding the immunogenicity of primary immunizations in middle-aged adults is lacking. We determined the immunogenicity of a primary meningococcal vaccine towards which no or (very) low pre-vaccination immunity exists in middle-aged adults (NTR4636).MethodsA vaccine containing multiple meningococcal groups (tetravalent) conjugated to tetanus toxoid (MenACWY-TT) was administered to middle-aged adults (50–65 years of age, N = 204) in a phase IV single-center and open-label study. Blood samples were taken pre-, 7 days, 28 days, and 1 year post-vaccination. Functional antibody titers were measured with the serum bactericidal assay (SBA). Meningococcal- and tetanus-specific antibody responses were determined with a fluorescent bead-based multiplex immunoassay. A bi-exponential decay model was used to estimate long-term protection.ResultsIn the majority of the participants, the meningococcal vaccine clearly induced naïve responses to meningococci W (MenW) and meningococci Y (MenY) as compared to a booster response to meningococci C (MenC). After 28 days, 94, 99, and 97% of the participants possessed a protective SBA titer for MenC, MenW, and MenY, respectively, which was maintained in 76, 94, and 86% 1 year post-vaccination. At this 1-year time point, significantly lower SBA titers were found in participants without a pre-vaccination SBA titer. Overall, protective antibody titers were predicted to persist after 10 years in 40–60% of the participants. The SBA titers correlated well with the meningococcal-specific IgM responses, especially for MenW and MenY. Interestingly, these IgM responses were negatively correlated with age.ConclusionPrimary immunization with a tetravalent meningococcal vaccine was highly immunogenic in middle-aged adults, inducing protective antibody titers in the vast majority of the participants lasting for at least 1 year. The age-related decrease in highly functional IgM responses argues in favor of vaccination against de novo antigens before reaching old age and, hence, middle-aged persons are an age group of interest for future vaccine interventions to protect the aging population. |
| first_indexed | 2024-12-22T00:15:59Z |
| format | Article |
| id | doaj.art-db54e80c5e534bd9967a711fd06112b7 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T00:15:59Z |
| publishDate | 2017-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-db54e80c5e534bd9967a711fd06112b72022-12-21T18:45:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-07-01810.3389/fimmu.2017.00817268032Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged AdultsMarieke van der Heiden0Marieke van der Heiden1Annemieke M. H. Boots2Axel A. Bonacic Marinovic3Lia G. H. de Rond4Marjan van Maurik5Irina Tcherniaeva6Guy A. M. Berbers7Anne-Marie Buisman8Centre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, NetherlandsDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, NetherlandsIntroductionVaccine responses are often reduced in the elderly, leaving part of the elderly population vulnerable to infectious diseases. Timely vaccination may offer a solution for strengthening memory immunity before reaching old age, which classifies middle-aged persons as a target age group for vaccine interventions. However, knowledge regarding the immunogenicity of primary immunizations in middle-aged adults is lacking. We determined the immunogenicity of a primary meningococcal vaccine towards which no or (very) low pre-vaccination immunity exists in middle-aged adults (NTR4636).MethodsA vaccine containing multiple meningococcal groups (tetravalent) conjugated to tetanus toxoid (MenACWY-TT) was administered to middle-aged adults (50–65 years of age, N = 204) in a phase IV single-center and open-label study. Blood samples were taken pre-, 7 days, 28 days, and 1 year post-vaccination. Functional antibody titers were measured with the serum bactericidal assay (SBA). Meningococcal- and tetanus-specific antibody responses were determined with a fluorescent bead-based multiplex immunoassay. A bi-exponential decay model was used to estimate long-term protection.ResultsIn the majority of the participants, the meningococcal vaccine clearly induced naïve responses to meningococci W (MenW) and meningococci Y (MenY) as compared to a booster response to meningococci C (MenC). After 28 days, 94, 99, and 97% of the participants possessed a protective SBA titer for MenC, MenW, and MenY, respectively, which was maintained in 76, 94, and 86% 1 year post-vaccination. At this 1-year time point, significantly lower SBA titers were found in participants without a pre-vaccination SBA titer. Overall, protective antibody titers were predicted to persist after 10 years in 40–60% of the participants. The SBA titers correlated well with the meningococcal-specific IgM responses, especially for MenW and MenY. Interestingly, these IgM responses were negatively correlated with age.ConclusionPrimary immunization with a tetravalent meningococcal vaccine was highly immunogenic in middle-aged adults, inducing protective antibody titers in the vast majority of the participants lasting for at least 1 year. The age-related decrease in highly functional IgM responses argues in favor of vaccination against de novo antigens before reaching old age and, hence, middle-aged persons are an age group of interest for future vaccine interventions to protect the aging population.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00817/fullimmunosenescenceagingmiddle-agedprimary immunizationIgMde novo antigens |
| spellingShingle | Marieke van der Heiden Marieke van der Heiden Annemieke M. H. Boots Axel A. Bonacic Marinovic Lia G. H. de Rond Marjan van Maurik Irina Tcherniaeva Guy A. M. Berbers Anne-Marie Buisman Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults Frontiers in Immunology immunosenescence aging middle-aged primary immunization IgM de novo antigens |
| title | Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults |
| title_full | Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults |
| title_fullStr | Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults |
| title_full_unstemmed | Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults |
| title_short | Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults |
| title_sort | novel intervention in the aging population a primary meningococcal vaccine inducing protective igm responses in middle aged adults |
| topic | immunosenescence aging middle-aged primary immunization IgM de novo antigens |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00817/full |
| work_keys_str_mv | AT mariekevanderheiden novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT mariekevanderheiden novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT annemiekemhboots novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT axelabonacicmarinovic novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT liaghderond novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT marjanvanmaurik novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT irinatcherniaeva novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT guyamberbers novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults AT annemariebuisman novelinterventionintheagingpopulationaprimarymeningococcalvaccineinducingprotectiveigmresponsesinmiddleagedadults |